Dear Readers,

I am delighted to share some thrilling news with you about Translational Gastroenterology and Hepatology (TGH). Our esteemed journal has reached significant milestones, marking a momentous chapter in our journey together.

I am thrilled to announce that TGH has achieved its first impact factor for the 2022 citation year, with a rating of 3. This remarkable achievement highlights the exceptional quality of the research published in TGH and underscores its growing influence in the field of gastroenterology and hepatology. I extend my heartfelt appreciation to all the authors, reviewers, and editorial team members who have contributed to this success. Your unwavering dedication and hard work have been instrumental in shaping TGH into the esteemed journal it is today.

Additionally, I am pleased to inform you that TGH has received a CiteScore of 7.2 for 2022. This notable accomplishment further emphasizes the journal's significance and impact within the scientific community. It is a testament to the high caliber of research published in TGH and the valuable contributions of our authors.

In celebration of these remarkable milestones, I invite you to join us in commemorating this special moment. I would like to extend my sincere gratitude to each of you for your continuous support and engagement with TGH. Your readership and active participation have been invaluable in shaping the journal's growth and success.

Furthermore, I would like to express my deep appreciation to the diligent members of our editorial office, whose unwavering efforts have ensured the excellence and integrity of TGH. Their commitment to maintaining the highest standards of scholarly publishing has been instrumental in achieving these milestones.

Once again, I extend my warmest congratulations to the entire TGH community on these remarkable achievements. We remain steadfast in our commitment to pursuing excellence, publishing cutting-edge research, and providing a platform for impactful contributions in the field of gastroenterology and hepatology. Together, we will continue shaping the future of our discipline.

Thank you for your continued support, and I eagerly anticipate your ongoing engagement with TGH.

With best regards,

I have been honored to be on the editorial board of mHealth. The excellent quality of the editorial staff makes the entire process of writing, reviewing, and publishing a joy.

CDT review articles, particularly those comprising special series issues, are world class! Residents and fellows across specialties have taken notice. It is no surprise that the impact factor of the journal is soaring.

It has been a pleasure to follow the development of TLCR almost from the beginning and meet the enthusiastic young team implementing this project. In a very short time, TLCR has become one of the leading international lung cancer journals and a must-read for everyone involved in this topic.

We live in a transformative and innovative time, and medicine is also experiencing such change. The best way to approach this time is through a multidisciplinary approach. Translation Lung Cancer Research (TLCR) is one of the best platforms for this, covering genomics, imaging, biomarkers, and state-of-the-art treatment. TLCR has been contributing to innovation in lung cancer research and practices, and I am confident that it will continue to do so.

I have witnessed the growth and relevance of the CDT journal over the years, and happy to be part of the Editorial Board. The topics of the papers are well chosen, of high quality and highly relevant from a clinical and research perspective. I see a great future for the CDT journal.